秘鲁市场上销售的非专利药拉米夫定 150 毫克片剂与创新药 Epivir 的溶解曲线比较评估。

Q3 Medicine
Malena Castañeda-Alarcón, Encarna García-Montoya, Javier Rodríguez-Calzado, María Flores-Rodríguez, Miguel Grande-Ortíz, Luis Moreno-Exebio
{"title":"秘鲁市场上销售的非专利药拉米夫定 150 毫克片剂与创新药 Epivir 的溶解曲线比较评估。","authors":"Malena Castañeda-Alarcón, Encarna García-Montoya, Javier Rodríguez-Calzado, María Flores-Rodríguez, Miguel Grande-Ortíz, Luis Moreno-Exebio","doi":"10.17843/rpmesp.2024.411.12821","DOIUrl":null,"url":null,"abstract":"<p><p>Lamivudine is one of the most prescribed drugs in the world, and is used to treat human immunodeficiency and hepatitis B. This study aimed to evaluate the quality attributes and compare the dissolution profiles of two batches (A and B) of generic lamivudine 150 mg tablets with the innovator drug Epivir 150 mg tablets. We conducted an analytical, experimental, cross-sectional study, and used a spectrophotometric method at a wavelength of maximum absorption (λ) corresponding to 270 nm, to measure the percentage of dissolved drug. The study evaluated identification, content, dissolution and mass uniformity. Apparatus 2 USP (Paddle) 75 rpm, 900 mL of dissolution medium (37 ± 0.5 °C) was used in three dissolution media: pH 1.2; 4.5 and 6.8. Samples of 5 mL were obtained at 5, 10, 15, 20 and 30 min. Both batches of generic lamivudine (A and B) were found to have the same dissolution kinetic profile as the innovator drug. Both formulations met the criteria of very fast dissolving (85% dissolved in 15 min), and fast dissolving (85% dissolved in 30 min) drugs. Therefore, it was not necessary to calculate the similarity factor. We concluded that generic drugs A and B are in vitro equivalents to the innovator drug Epivir. Motivation for the study. To evaluate the quality of antiretroviral drugs used in the treatment of HIV dispensed in the HAART Program of the Ministry of Health of Peru. Main findings. Two batches of generic lamivudine drugs were found to achieve a dissolution rate greater than 85% at 15 min, being equivalent in vitro to the reference product Epivir. Implications. There is a need to apply the current regulations regarding equivalence between drugs by the regulatory authority prior to their authorization and to include dissolution profile tests as a requirement in public drug purchases, especially in national strategies (HIV, TB, etc.), in order to ensure quality products for the population.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"41 1","pages":"69-75"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152243/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative evaluation of dissolution profiles of the generic drug lamivudine 150 mg tablet marketed in Peru vs. the innovative Epivir.\",\"authors\":\"Malena Castañeda-Alarcón, Encarna García-Montoya, Javier Rodríguez-Calzado, María Flores-Rodríguez, Miguel Grande-Ortíz, Luis Moreno-Exebio\",\"doi\":\"10.17843/rpmesp.2024.411.12821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lamivudine is one of the most prescribed drugs in the world, and is used to treat human immunodeficiency and hepatitis B. This study aimed to evaluate the quality attributes and compare the dissolution profiles of two batches (A and B) of generic lamivudine 150 mg tablets with the innovator drug Epivir 150 mg tablets. We conducted an analytical, experimental, cross-sectional study, and used a spectrophotometric method at a wavelength of maximum absorption (λ) corresponding to 270 nm, to measure the percentage of dissolved drug. The study evaluated identification, content, dissolution and mass uniformity. Apparatus 2 USP (Paddle) 75 rpm, 900 mL of dissolution medium (37 ± 0.5 °C) was used in three dissolution media: pH 1.2; 4.5 and 6.8. Samples of 5 mL were obtained at 5, 10, 15, 20 and 30 min. Both batches of generic lamivudine (A and B) were found to have the same dissolution kinetic profile as the innovator drug. Both formulations met the criteria of very fast dissolving (85% dissolved in 15 min), and fast dissolving (85% dissolved in 30 min) drugs. Therefore, it was not necessary to calculate the similarity factor. We concluded that generic drugs A and B are in vitro equivalents to the innovator drug Epivir. Motivation for the study. To evaluate the quality of antiretroviral drugs used in the treatment of HIV dispensed in the HAART Program of the Ministry of Health of Peru. Main findings. Two batches of generic lamivudine drugs were found to achieve a dissolution rate greater than 85% at 15 min, being equivalent in vitro to the reference product Epivir. Implications. There is a need to apply the current regulations regarding equivalence between drugs by the regulatory authority prior to their authorization and to include dissolution profile tests as a requirement in public drug purchases, especially in national strategies (HIV, TB, etc.), in order to ensure quality products for the population.</p>\",\"PeriodicalId\":53651,\"journal\":{\"name\":\"Revista Peruana de Medicina de Experimental y Salud Publica\",\"volume\":\"41 1\",\"pages\":\"69-75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152243/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Peruana de Medicina de Experimental y Salud Publica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17843/rpmesp.2024.411.12821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Peruana de Medicina de Experimental y Salud Publica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17843/rpmesp.2024.411.12821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

拉米夫定是世界上处方量最大的药物之一,用于治疗人类免疫缺陷和乙型肝炎。本研究旨在评估两个批次(A 和 B)拉米夫定 150 毫克仿制药片与创新药 Epivir 150 毫克片剂的质量属性并比较其溶解曲线。我们进行了一项分析、实验和横断面研究,并使用分光光度法在最大吸收波长 (λ) 相当于 270 纳米的波长上测量溶解药物的百分比。研究评估了鉴定、含量、溶解度和质量均匀性。仪器 2 USP(桨式)75 转/分,900 毫升溶解介质(37 ± 0.5 °C)用于三种溶解介质:pH 值 1.2、4.5 和 6.8。分别在 5、10、15、20 和 30 分钟取 5 mL 样品。结果表明,两个批次的拉米夫定仿制药(A 和 B)与创新药具有相同的溶解动力学特征。两种制剂均符合极速溶解(15 分钟内溶解 85%)和快速溶解(30 分钟内溶解 85%)药物的标准。因此,没有必要计算相似系数。我们的结论是,仿制药 A 和 B 与创新药 Epivir 具有体外等效性。研究动机评估秘鲁卫生部 HAART 计划中用于治疗 HIV 的抗逆转录病毒药物的质量。主要发现。发现两个批次的拉米夫定非专利药在 15 分钟内的溶解度大于 85%,与参考产品 Epivir 的体外溶解度相当。影响。有必要在药品授权之前,由监管机构对药品之间的等效性实施现行规定,并将溶解度曲线测试作为公共药品采购的一项要求,特别是在国家战略(艾滋病、结核病等)中,以确保为民众提供优质产品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative evaluation of dissolution profiles of the generic drug lamivudine 150 mg tablet marketed in Peru vs. the innovative Epivir.

Lamivudine is one of the most prescribed drugs in the world, and is used to treat human immunodeficiency and hepatitis B. This study aimed to evaluate the quality attributes and compare the dissolution profiles of two batches (A and B) of generic lamivudine 150 mg tablets with the innovator drug Epivir 150 mg tablets. We conducted an analytical, experimental, cross-sectional study, and used a spectrophotometric method at a wavelength of maximum absorption (λ) corresponding to 270 nm, to measure the percentage of dissolved drug. The study evaluated identification, content, dissolution and mass uniformity. Apparatus 2 USP (Paddle) 75 rpm, 900 mL of dissolution medium (37 ± 0.5 °C) was used in three dissolution media: pH 1.2; 4.5 and 6.8. Samples of 5 mL were obtained at 5, 10, 15, 20 and 30 min. Both batches of generic lamivudine (A and B) were found to have the same dissolution kinetic profile as the innovator drug. Both formulations met the criteria of very fast dissolving (85% dissolved in 15 min), and fast dissolving (85% dissolved in 30 min) drugs. Therefore, it was not necessary to calculate the similarity factor. We concluded that generic drugs A and B are in vitro equivalents to the innovator drug Epivir. Motivation for the study. To evaluate the quality of antiretroviral drugs used in the treatment of HIV dispensed in the HAART Program of the Ministry of Health of Peru. Main findings. Two batches of generic lamivudine drugs were found to achieve a dissolution rate greater than 85% at 15 min, being equivalent in vitro to the reference product Epivir. Implications. There is a need to apply the current regulations regarding equivalence between drugs by the regulatory authority prior to their authorization and to include dissolution profile tests as a requirement in public drug purchases, especially in national strategies (HIV, TB, etc.), in order to ensure quality products for the population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Peruana de Medicina de Experimental y Salud Publica
Revista Peruana de Medicina de Experimental y Salud Publica Medicine-Public Health, Environmental and Occupational Health
CiteScore
3.00
自引率
0.00%
发文量
57
审稿时长
12 weeks
期刊介绍: La Revista Peruana de Medicina Experimental y Salud Pública (RPMESP) es el órgano oficial de difusión científica del Instituto Nacional de Salud (INS) del Perú. Es una publicación arbitrada por pares, de periodicidad trimestral, de ámbito y difusión mundial, indizada en MEDLINE/Index Medicos, SCOPUS, EMBASE, SciELO Salud Pública y otras bases de datos internacionales. La RPMESP es distribuida en su versión impresa y electrónica, con acceso gratuito a texto completo. La RPMESP publica artículos referidos a temas del ámbito biomédico y de salud pública, resaltando aportes prácticos, que contribuyan a mejorar la situación de salud del país y de la región. Propicia el intercambio de la experiencia científica en salud entre instituciones y personas dedicadas a la investigación dentro y fuera del Perú a fin de promover el avance y la aplicación de la investigación en salud.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信